Brown Advisory Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Brown Advisory Securities’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,865	Closed	-$338K	–	326
2016 Q2	$338K	Sell	2,865 -1,148	-29%	-$163K	0.11%	199
2016 Q1	$559K	Buy	4,013 +425	+12%	+$62.4K	0.18%	132
2015 Q4	$688K	Sell	3,588 -275	-7%	-$48K	0.23%	98
2015 Q3	$609K	Sell	3,863 -34	-0.9%	-$6.2K	0.22%	109
2015 Q2	$702K	Buy	3,897 +1,562	+67%	+$270K	0.23%	100
2015 Q1	$406K	Buy	+2,335	New	+$423K	0.14%	169

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Brown Advisory Securities's ALXN Position: Q3 2016 in Review

Brown Advisory Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 2,865 shares — an estimated $338K sold.

Brown Advisory Securities first reported a position in ALXN in Q1 2015 and held it in 6 quarters. The position peaked at $702K in Q2 2015. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Brown Advisory Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Brown Advisory Securities sold 2,865 Alexion Pharmaceuticals shares in Q3 2016, an estimated $338K.
Brown Advisory Securities first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Brown Advisory Securities's Alexion Pharmaceuticals position peaked at $702K in Q2 2015.
517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Brown Advisory Securities's 13F filing for Q3 2016, filed 10 Nov 2016.